{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalEntity"
  ],
  "@id": "aku-051-mvt-treatment",
  "metadata": {
    "version": "1.0.0",
    "created": "2025-12-30T06:30:00.000Z",
    "contributors": [
      "copilot-agent",
      "vascular-surgery-knowledge-base"
    ],
    "confidence": 0.91,
    "status": "enhanced",
    "last_updated": "2025-12-30T06:30:00.000Z",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/mesenteric-ischemia",
    "type": "treatment",
    "difficulty": "advanced",
    "importance": "high",
    "aku_id": "051",
    "keywords": [
      "mesenteric venous thrombosis",
      "MVT treatment",
      "anticoagulation",
      "thrombolysis",
      "venous ischemia"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "treatment",
    "isNativeDomain": true
  },
  "content": {
    "statement": "aku-051-mvt-treatment is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Mesenteric-Ischemia that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding aku-051-mvt-treatment helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of aku-051-mvt-treatment include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of aku-051-mvt-treatment."
    }
  },
  "anticoagulation": {
    "initial_therapy": {
      "agents": [
        {
          "drug": "Unfractionated heparin (UFH)",
          "dosing": "Bolus 80 U/kg, then 18 U/kg/hr; target aPTT 1.5-2.5x control",
          "advantage": "Reversible if surgery needed",
          "use": "Preferred if surgery possible"
        },
        {
          "drug": "Low molecular weight heparin (LMWH)",
          "dosing": "Enoxaparin 1 mg/kg SC q12h or equivalent",
          "advantage": "Predictable response, no monitoring needed",
          "caution": "Less reversible than UFH"
        }
      ],
      "timing": "Initiate immediately upon diagnosis\u2014do not wait for confirmatory tests if clinical suspicion high",
      "duration_initial": "Continue until clinically stable and transitioned to oral anticoagulation"
    },
    "transition_to_oral": {
      "timing": "When patient tolerating oral intake and stable",
      "options": [
        {
          "drug": "Warfarin",
          "target": "INR 2.0-3.0",
          "overlap": "Overlap with heparin for 5+ days and INR therapeutic for 24+ hours",
          "advantage": "Established, reversible",
          "disadvantage": "Requires monitoring, dietary interactions"
        },
        {
          "drug": "Direct oral anticoagulants (DOACs)",
          "examples": [
            "Rivaroxaban",
            "Apixaban",
            "Edoxaban"
          ],
          "advantage": "No monitoring, fixed dosing, fewer interactions",
          "considerations": [
            "Limited data specifically in MVT (extrapolated from VTE trials)",
            "May be preferred in patients with cancer (rivaroxaban, edoxaban)",
            "Avoid if severe liver disease or renal impairment"
          ],
          "trend": "Increasing use; non-inferior to warfarin in VTE"
        }
      ]
    },
    "duration": {
      "provoked_mvt": {
        "definition": "Identifiable transient risk factor (surgery, infection, medications)",
        "duration": "3-6 months",
        "rationale": "Risk factor removed; recurrence risk lower"
      },
      "unprovoked_mvt": {
        "definition": "No identifiable risk factor",
        "duration": "Minimum 6 months; consider indefinite",
        "rationale": "Higher recurrence risk; weigh bleeding vs thrombosis"
      },
      "prothrombotic_state": {
        "examples": [
          "Factor V Leiden",
          "Protein C/S deficiency",
          "Antithrombin deficiency",
          "Antiphospholipid syndrome",
          "Myeloproliferative neoplasm"
        ],
        "duration": "Lifelong anticoagulation",
        "rationale": "Persistent high recurrence risk"
      },
      "malignancy_associated": {
        "agent": "LMWH or DOAC preferred over warfarin",
        "duration": "Duration of cancer treatment; indefinite if persistent",
        "guidance": "Per oncology VTE guidelines"
      }
    }
  },
  "supportive_care": {
    "bowel_rest": {
      "indication": "NPO initially for all acute MVT",
      "duration": "Until pain improving and bowel function returning",
      "nutrition": "TPN if prolonged NPO expected"
    },
    "fluid_resuscitation": {
      "rationale": "Third-spacing into bowel wall and mesentery",
      "goal": "Adequate urine output, improving lactate"
    },
    "antibiotics": {
      "indication": "Broad-spectrum coverage for translocation prevention",
      "regimen": "Same as for arterial ischemia (pip-tazo, carbapenem)"
    },
    "pain_control": {
      "approach": "Opioids as needed; monitor for ileus"
    }
  },
  "interventional_therapy": {
    "catheter_directed_thrombolysis": {
      "indications": [
        "Extensive SMV/portal vein thrombosis",
        "Worsening symptoms despite anticoagulation",
        "No peritonitis or necrosis"
      ],
      "approach": {
        "transhepatic": "Access portal vein percutaneously through liver",
        "transjugular": "TIPS approach with thrombolysis"
      },
      "agents": "tPA infusion over 24-72 hours",
      "monitoring": "Serial imaging to assess response; watch for bleeding",
      "outcomes": "May improve portal vein patency; limited comparative data"
    },
    "mechanical_thrombectomy": {
      "emerging": "Pharmacomechanical approaches being explored",
      "evidence": "Limited; case series only"
    },
    "tips_for_portal_hypertension": {
      "role": "Not first-line; consider if chronic portal hypertension develops after MVT"
    }
  },
  "surgical_intervention": {
    "indications": [
      "Peritonitis (peritoneal signs on exam)",
      "Signs of bowel necrosis (hemodynamic instability, acidosis, bloody stool)",
      "Failure to improve with anticoagulation",
      "Perforation"
    ],
    "procedure": {
      "exploration": "Laparotomy to assess bowel viability",
      "resection": "Remove frankly necrotic bowel; preserve maximum length",
      "venous_thrombectomy": "Generally NOT attempted (technically difficult, clot extends into small veins)",
      "second_look": "Consider if viability questionable"
    },
    "outcomes": {
      "mortality_with_necrosis": "20-50%",
      "sbs_risk": "If extensive resection required"
    }
  },
  "hypercoagulable_workup": {
    "timing": "After acute phase; some tests affected by acute thrombosis and anticoagulation",
    "tests_to_consider": [
      {
        "test": "Factor V Leiden",
        "timing": "Any time"
      },
      {
        "test": "Prothrombin G20210A",
        "timing": "Any time"
      },
      {
        "test": "Protein C activity",
        "timing": "Off warfarin for 2+ weeks"
      },
      {
        "test": "Protein S activity",
        "timing": "Off warfarin for 2+ weeks"
      },
      {
        "test": "Antithrombin activity",
        "timing": "Off heparin; affected by acute thrombosis"
      },
      {
        "test": "Lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein",
        "timing": "Best tested off anticoagulation; confirm 12 weeks later"
      },
      {
        "test": "JAK2 mutation",
        "timing": "If myeloproliferative neoplasm suspected"
      },
      {
        "test": "Homocysteine",
        "timing": "Any time"
      }
    ],
    "additional_workup": {
      "imaging": "CT or MRI to rule out occult malignancy (especially pancreatic, hepatic)",
      "hematology_referral": "If inherited thrombophilia or myeloproliferative disorder suspected"
    }
  },
  "prognosis": {
    "short_term_survival": {
      "with_anticoagulation_alone": "85-95% if no necrosis",
      "with_surgery": "50-80% depending on extent"
    },
    "recurrence_risk": {
      "without_anticoagulation": "20-40% at 5 years",
      "with_anticoagulation": "5-10% at 5 years"
    },
    "long_term_sequelae": {
      "portal_hypertension": "5-10% develop chronic portal hypertension",
      "intestinal_stricture": "Rare, from healed ischemic injury"
    }
  },
  "clinical_pearls": [
    {
      "pearl": "MVT has a more forgiving timeline than arterial ischemia\u2014anticoagulation is the first-line treatment, not surgery",
      "implication": "Resist the urge to rush to surgery; anticoagulation allows many patients to avoid operation"
    },
    {
      "pearl": "An underlying hypercoagulable state is found in 60-80% of MVT cases\u2014workup is essential to guide anticoagulation duration",
      "implication": "Perform thrombophilia workup after acute phase; results dictate lifelong vs. time-limited therapy"
    },
    {
      "pearl": "DOACs are increasingly used for MVT, extrapolating from VTE data, though warfarin remains well-established",
      "implication": "Both are acceptable; choose based on patient factors and monitoring capability"
    },
    {
      "pearl": "Peritonitis mandates surgery\u2014anticoagulation cannot salvage necrotic bowel",
      "implication": "Don't delay operation hoping anticoagulation will work if peritoneal signs are present"
    }
  ],
  "relationships": {
    "prerequisites": [
      {
        "aku_id": "urn:wskg:medicine:surgery:vascular:mesenteric-ischemia:009",
        "title": "Mesenteric Venous Thrombosis Mechanism",
        "relationship": "pathophysiology_foundation"
      },
      {
        "aku_id": "urn:wskg:medicine:surgery:vascular:mesenteric-ischemia:020",
        "title": "Anticoagulation Therapy",
        "relationship": "treatment_foundation"
      }
    ],
    "enables": [
      {
        "aku_id": "urn:wskg:medicine:surgery:vascular:mesenteric-ischemia:035",
        "title": "Surveillance Protocols",
        "relationship": "follow_up"
      }
    ],
    "related_concepts": [
      {
        "aku_id": "urn:wskg:medicine:surgery:vascular:mesenteric-ischemia:023",
        "title": "Bowel Resection",
        "relationship": "surgical_intervention"
      },
      {
        "aku_id": "urn:wskg:medicine:surgery:vascular:mesenteric-ischemia:031",
        "title": "Mortality Outcomes",
        "relationship": "prognosis"
      }
    ],
    "cross_domain": [
      {
        "domain": "medicine/hematology/thrombophilia",
        "relationship": "underlying_etiology",
        "note": "Hypercoagulable workup essential"
      },
      {
        "domain": "medicine/oncology/paraneoplastic",
        "relationship": "occult_malignancy",
        "note": "MVT may herald occult cancer"
      }
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). aku-051-mvt-treatment. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}